Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies

Recurrent, metastatic disease represents the most frequent cause of death for patients with thyroid cancer, and radioactive iodine (RAI) remains a mainstay of therapy for these patients. Unfortunately, many thyroid cancer patients have tumors that no longer trap iodine, and hence are refractory to R...

Descripción completa

Detalles Bibliográficos
Autores principales: Aashiq, Mohamed, Silverman, Deborah A., Na’ara, Shorook, Takahashi, Hideaki, Amit, Moran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770909/
https://www.ncbi.nlm.nih.gov/pubmed/31533238
http://dx.doi.org/10.3390/cancers11091382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770909/
https://www.ncbi.nlm.nih.gov/pubmed/31533238
http://dx.doi.org/10.3390/cancers11091382

Ejemplares similares